Trial Profile

Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Malignant melanoma; Skin cancer
Focus Biomarker; Therapeutic Use
Acronyms NivoMela

Most Recent Events

01 Nov 2022 Status changed from recruiting to active, no longer recruiting.
19 May 2022 Planned End Date changed from 1 Jun 2027 to 1 Jan 2028.
19 May 2022 Planned primary completion date changed from 1 Jun 2027 to 1 Sep 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com